Objective: To test common genetic variants for association with seasonality (seasonal changes in mood and behavior) and to investigate whether there are shared genetic risk factors between psychiatric disorders and seasonality.
A lthough seasonal changes in mood and behavior (seasonality) have been recognized for a long time, 1 seasonal affective disorder (SAD) was first defined by Rosenthal et al 2 as a syndrome with recurrent depression in fall and winter and alleviation of depressive symptoms in spring and summer. In addition, while SAD is not a distinct clinical entity in the fourth and fifth iterations of the Diagnostic and Statistical Manual of Mental Disorders (DSM), these manuals include a longitudinal seasonal pattern specifier for major depressive episodes with a consistent temporal relationship with specific times of the year, such as fall and winter, in the past 2 years in individuals with recurrent major depressive disorder (MDD) and bipolar I or II disorder (BD), with the depressive episodes undergoing full remission or, less commonly, a switch to hypomanic or manic symptoms at others times of the year, such as spring or summer. [3] [4] [5] Rosenthal 5 has argued from many lines of evidence that SAD should be considered an independent clinical entity rather than a seasonal mood specifier. Seasonal affective disorder is characterized by symptoms of depression, such as changes in sleep pattern, fluctuations in weight, decreased energy, and reduced social activities at a particular period of the year, followed by at least partial remission when the season changes. 6 The most common form is SAD with a winter depression pattern (SAD). 2 Symptoms of SAD are particularly responsive to bright light treatment. [7] [8] [9] [10] Contrary to common expectations, patients with SAD can manifest severe symptomatology 11, 12 and cognitive deficits 12 similar to nonseasonal depression. 12 Seasonal affective disorder as a clinical diagnosis represents the extreme of a spectrum of seasonality that exists in the population. Many individuals experience seasonal changes in mood and behavior at subclinical levels that can cause significant distress and impairment, 13, 14 while others may experience only very subtle changes. 15 Family studies of SAD prevalence report increased prevalence of SAD in first-degree relatives of patients with SAD. 16, 17 A previous analysis of a large epidemiologic twin study, 18 a subset of which is included in genetic analyses of our data, estimated that genetic factors account for 29% of the overall variance in seasonality in men and women as assessed by the Seasonal Pattern Assessment Questionnaire (SPAQ). 19 Family studies have also shown increased prevalence of nonseasonal depression in the families of individuals with SAD, but the question of whether seasonality and depression are distinct in terms of the genetic risk factors that predispose to them remains unanswered.
There are differences between MDD with seasonal pattern and BD with seasonal pattern: for instance, the recurrence of the seasonal depression and severity of the course, with higher rates of hospitalization in the bipolar form. 20 Importantly, even the unipolar form of SAD has been previously conceptualized clinically as belonging to the bipolar spectrum. 21 While a number of candidate gene analyses of SAD have been performed, [22] [23] [24] [25] [26] [27] no consistently replicable findings have been gleaned from candidate gene studies of SAD.
Genome-wide association studies (GWASs) have been successful in mapping genetic variants that increase risk of schizophrenia 28, 29 and BD 30 ; however, large sample sizes have been required to detect them. No GWASs have as yet been performed for SAD.
Furthermore, the molecular genetics era has given valuable insights into the etiology of psychiatric disorders that may influence diagnosis in the future. For example, it has recently been demonstrated that much of the genetic risk is shared between psychiatric disorders. 31 The aim of this study is to perform a GWAS of seasonality in a population of Australian twins and an Old Order Amish population from Lancaster County, Pennsylvania, and to investigate the genetic overlap between seasonality and 3 psychiatric disorders-major depressive disorder (MDD), BD, and schizophrenia.
METHOD

Seasonal Pattern Assessment Questionnaire
A well-studied SAD screening and research questionnaire, the SPAQ 32 evaluates SAD by estimating a score of global seasonality calculated by responses on a Likert scale of 0-4 for each of 6 indices of seasonality, the degree to which these changes cause impaired functioning (the problem scale, ranging from 0 to 5), and the season(s) indicated by the participant as representing the time during which they feel "worst. " For cases with incomplete responses on the global seasonality indices, the global seasonality score was estimated from the proportion of responses.
Australian Samples
Participants were drawn from 2 studies conducted between 1988 and 1990 and between 2010 and 2013 at the Queensland Institute of Medical Research. The first study, which has been described previously, 18 involved mailing a questionnaire that included the SPAQ to 3,808 twin pairs from the Australian Twin Registry. A total of 2,487 twin pairs and 687 singletons returned questionnaires with responses to the SPAQ. A total of 2,605 individuals provided both genetic and phenotypic information.
The second study, the Midwest Alcohol Research Center study, is a collaborative study between investigators at Queensland Institute of Medical Research and Washington University in St Louis, Missouri, that was initiated to investigate the effects of severe childhood and adult trauma on alcohol consumption and alcohol dependence. The target sample (N = 3,607 individuals) had previously participated in a GWAS of these alcohol-related outcomes (Heath et al 33 ). Participants undertook a phone interview with a trained interviewer with the aim of assessing lifetime history of severe childhood and adult environmental stressors. The SPAQ was included as part of the protocol. At the time of analysis, a total of 686 individuals had completed an interview and provided responses to the SPAQ. After removal of ancestry outliers, a total of 664 individuals provided both phenotype and genotype information.
The overall sample size for inclusion in the GWAS was 3,269. The total sample providing phenotypic information was 6,347. All participants gave informed consent, and the study was approved by the ethics board of Queensland Institute of Medical Research. Descriptive statistics are given in Table 1 .
In the interest of reducing the multiple testing statistical burden, it was decided to analyze the global score and not the symptoms individually.
As the Australian twin sample was recruited from different regions of the country, a state of residence fixed effect was included in a linear model along with age and sex, and the residuals of the global seasonality scores after adjusting for these effects were tested for association. Global seasonality scores from all phenotyped individuals were used to extract the residuals.
Clinical Points
Our study provides evidence for an expected overlap between ■ seasonality of mood and bipolar disorder and a somewhat unexpected genetic overlap between seasonality of mood and schizophrenia. There was no genetic overlap between major depression and seasonality.
If replicated, our results would imply that seasonal changes ■ in mood and behavior should be evaluated not only in individuals diagnosed with mood disorders but also in patients with schizophrenia. Clinical symptoms that overlap between seasonal affective disorder and schizophrenia include cognitive impairment, social withdrawal, and sleep changes, and both conditions share associations with certain metabolic abnormalities, such as vitamin D deficiency.
Future research may specifically focus on molecular ■ pathways mediating the overlap between seasonality and schizophrenia and bipolar disorder, potentially leading to theoretical advances and novel therapeutic interventions. Genotyping. Full details of the genotyping, imputation, and quality control procedures are given in the supplementary material. After genotyping, quality control, and imputation, a total number of 2,380,486 single nucleotide polymorphisms (SNPs) were included.
Amish
Participants in the study were Amish individuals enrolled in community-based studies [34] [35] [36] [37] conducted between May 2010 and December 2011 at the University of Maryland and University of Maryland's Amish Research Clinic in Lancaster County, Pennsylvania. The participants consented to be contacted for future studies. Seasonal Pattern Assessment Questionnaires were sent by mail to 2,260 such Amish individuals, both male and female and all above the age of 18 years. The letter contained, in addition to the SPAQ, a statement that completion of the SPAQ implied documented informed consent for the study and directions on completion of the questionnaire. This protocol was approved by the institutional review board of the University of Maryland. Initial mailings were done in May 2010. A subsequent mailing in September 2010 was done for those who had not responded to the initial mailing. All responses received before December 31, 2011, numbering a total of 1,306 (response rate 57.8%), comprised the dataset.
Using a convenience subsample of 68 subjects administered the SPAQ twice over a 4-month period, the test-retest reliability of the global seasonality and problem rating score (PRS) in the Amish was adequate using Cronbach α (global seasonality, α = .87; PRS, α = .79) 38 and comparable to that in the general population.
39
Genotyping. Genotyping was performed using the Affymetrix GeneChip Human Mapping 500 K or 6.0 Array set (Affymetrix, Santa Clara, California). Genotype calls were made using the Bayesian robust linear model with mahalanobis distance classifier genotype calling algorithm. A total of 364,336 informative autosomal SNPs that passed quality control were included in the analysis. Markov Chain Haplotyping (MaCH) 40 was used for imputation (release 22, build 36) after applying the following exclusion filters: (1) SNP not found in HapMap; (2) frequency < 0.01; (3) HardyWeinberg P value < 1 × 10 −6 ; and (4) missingness > 0.05.
Association Analysis
Association testing in the Australian sample was performed in Merlin, 41, 42 using the dosage scores from the imputation. Merlin accounts for the relationship between individuals in the sample. Four ancestry principal components were included as covariates to correct for population stratification. Prior to this, those individuals with evidence of nonEuropean ancestry were removed from the analysis.
Association analysis in the Amish sample was performed using Mixed Models Analysis for Pedigrees and Populations (MMAP) software developed by J. R. O'Connell (http://edn. som.umaryland.edu/mmap/index.php), which accounts for family structure by conditioning the association of genotype with outcome on the relationship matrix (included as a random effect) and covariates (eg, age and sex). Meta-analysis was performed using the inverse variance weighting method in METAL. 43 
Statistical Power
We simulated a trait with a heritability of 0.29 using Merlin and estimated the statistical power to detect a variant with a minor allele frequency of 0.2 that explains 1% of the phenotypic variance in global seasonality. The Australian sample had 50.8% power to detect such a variant at the genome-wide significance threshold. The sample had 89% power to detect a variant explaining 1.5% of the phenotypic variance.
Profile Scoring
In the Australian dataset, we tested whether there is a genetic correlation between seasonality, measured by the global seasonality, and mood disorders, utilizing the results from the Psychiatric GWAS Consortium (PGC) GWAS analyses of schizophrenia, 28 BD, 30 and MDD 44 to generate genetic profile scores. A single twin from each pair was selected at random for analysis so as to exclude relatives so that the analysis set included 1,999 unrelated individuals. For each individual, 3 separate profile scores were generated based on the results from the PGC GWASs. The profile scoring methodology generates a single genetic "load" score for each individual by weighting each SNP by the log of the odds ratio estimated in the original study. In this way, SNPs with a larger predicted effect on risk to disease are given more weight in making the predictor. Linear regression of the profile score on the trait of interest allows for estimation of how well the profile score predicts the phenotype. This method was first described by Purcell et al 45 and used to demonstrate that there is overlap in the genetic risk factors for schizophrenia and BD.
We used the summary results from the PGC BD and schizophrenia GWAS analyses separately (downloaded from http://www.med.unc.edu/pgc). The schizophrenia study included 9,394 cases and 12,462 controls, and the BP study included 7,481 cases and 9,250 controls. These results had been clumped at r 2 < 0.25 to ensure that only the most significant SNP in a given linkage disequilibrium block is included in the analysis and that the same association signal is not included more than once. We also generated profile scores using association results from PGC MDD. 44 However, since samples from the Queensland Institute of Medical Research contribute to PGC MDD analysis, the PGC MDD data were reanalyzed with the Australian samples excluded, so as to remove any chance of overlap between the discovery and target samples. A total of 7,790 cases and 7,808 controls were included in the revised PGC MDD analysis. The results from this GWAS analysis were used in the MDD profile score analysis.
RESULTS
Genome-Wide Association Study
Results from the most significantly associated SNPs (P < 10 −5 ) from the Australian sample are shown in Supplementary eTable 1. No SNPs reached genome-wide significance in the initial GWAS. All SNPs that had a P value < 10 −4 and that were independent at r 2 < 0.5 or > 50 kilobase (kb) away from each other were tested for replication in the Amish sample. No SNPs passing the significance threshold in the Australian sample were replicated in the Amish with nominal significance (P < .05).
A total of 2,354,422 markers that were in common between the 2 studies were included in a meta-analysis of the 2 individual studies. No genes reached the genomewide significant threshold (P < 5 × 10 −8 ). The most significant SNP in the meta-analysis was rs11825064 (P = 1. 
Genetic Overlap Using Profile Scoring
The results for the profile score analysis for all 3 disorders are shown in Supplementary eTable 3. The results for BD and schizophrenia are also shown in Figure 1 . There is very strong evidence for genetic overlap between schizophrenia and seasonality (P < 1 × 10 −15 for genetic scores based on SNPs associated with schizophrenia at P < .5 or all SNPs) and milder evidence for genetic overlap between BD and seasonality (P = .004-.005 for genetic scores based on SNPs associated with schizophrenia at P < .1, P < .5, or all SNPs). The genetic risk score for schizophrenia accounted for up to 3.1% of the phenotypic variation in global seasonality. A nominally significant proportion of the variance in the global seasonality was explained by 427 SNPs, with P < .001 from the PGC schizophrenia GWAS (P = .0018, variance explained = 0.4%). The null hypothesis that the variance explained by all the schizophrenia SNPs is 0 was rejected (P = 1.53 × 10 −15 ). In contrast, genetic risk score for BD accounted for only 0.4% of the phenotypic variation in global seasonality (see Supplementary eTable 4) . No evidence for genetic overlap between MDD and seasonality was observed, as the amount of variance in global seasonality explained by the MDD polygenic scores was not significantly different from 0.
DISCUSSION
We performed a meta-analysis of 2 GWASs of the global seasonality derived from the SPAQ in a sample of twins from Australia and members of the Amish community in Pennsylvania. No genome-wide, significant loci were detected. The results of gene-mapping studies in other affective disorders indicate that a polygenic model, with many common alleles of small effect influencing risk, is likely to explain a significant proportion of the heritability of affected disorders. 28, [45] [46] [47] Our results suggest that common variants that are associated with seasonality and that have unusually large effect sizes are unlikely to exist. While the lack of power is a severe limitation of our study, our results will be useful for future meta-analyses of seasonality and SAD, and they provide a list of candidates that can be tested in other cohorts.
The differences between the 2 populations included in this study may have also increased the chances of negative findings. The geographical differences between Australia and the Northeast of the United States are substantial, and there are differences between the amount of sunshine and the day length in different seasons. Even within Australia, there is great variability in day length between cities. We have tried to account for these differences by including state as a covariate in the analysis; however, subtle differences may still exist.
Genetic differences between the populations also exist. The Amish are a genetically isolated population who may harbor unique genetic variants that predispose to seasonality that will not be detected in studies that include other populations. The heritability of seasonality was estimated to be 13.6% in the Old Order Amish, 39 a somewhat lower estimate than that in the Australian population-based sample. This indicates that genetic differences between individuals contribute less to the overall variance of seasonality in the Old Order Amish than in Australians. Furthermore, the prevalence of SAD in the Amish is the lowest of all white populations that have been assessed using the SPAQ. This implies that the Amish population is relatively resilient to seasonality. The profile scoring analyses were performed only in the Australian population and may therefore not be generalizable to the Amish. Among Anabaptists there is a low rate of psychosis. 48, 49 A further limitation of our study is that it did not include actual diagnosis of mental conditions. This would have Variance Explained (adjusted r 2 ) P < .001 P < .01 P < .1 P < . permitted the exclusion of those with a psychiatric diagnosis prior to the profile scoring, and therefore the ability to test for genetic overlap between these disorders and seasonality in those without another psychiatric comorbidity. The sample used for profile scoring is a population-based twin sample, so the prevalence of severe psychiatric disorders is likely to be low. It is noteworthy that genetic profile scores generated from the schizophrenia GWAS explain more variance in seasonality than those derived from the BD and MDD studies. This result is surprising given that seasonal pattern can be added as a modifier of a unipolar and bipolar depression diagnosis in DSM-5. In contrast, the seasonal pattern is not clinically or epidemiologically considered in association with schizophrenia. The finding that the schizophrenia profile scores explain a larger proportion of variance in the global seasonality may be due to differences between the GWASs from which the polygenic scores were generated. For instance, a larger sample size or better accuracy of diagnosis or lack of some other confounding source could lead to more accurate estimates of the true SNP effects in the schizophrenia GWAS compared to those of BD or MDD. Summing more accurate SNP effect estimates of over thousands of SNPs could lead to substantially more accurate polygenic scores.
In contrast to BD, MDD showed no evidence for genetic overlap with global seasonality in our sample. Conceptually, SAD has been considered as a condition on the spectrum of bipolarity, 21 even if major depression episodes alternate with periods of remission. To date, GWASs of MDD have failed to uncover any replicable common variants. One possible reason for this is that the estimates of the SNP effects from the MDD GWAS may be less accurate than those from the schizophrenia and BD GWASs. It has been argued that a GWAS of MDD has less power than a GWAS of schizophrenia or BD of the same sample size, simply reflecting that MDD is a more prevalent disorder, is potentially more heterogeneous, and has a lower proportion of risk explained by genetic factors. 50 Although seasonality of mood and general health has been observed since ancient times, seasonality of psychiatric symptoms (predominantly affective, but also psychotic and catatonic features as well as cognitive deficits) was clinically described in the early 19th century by Pinel and his student Esquirol, with additional early contributions by Griesinger, Kraepelin, and Kraines (reviewed by Wehr and Rosenthal 1 ). To our knowledge, our current report provides the first direct evidence at the molecular level for the overlap between seasonality and BD that has been previously suggested clinically. 21 While the association between seasonality of mood and schizophrenia was unexpected, a hint of a relationship was reported in small samples at high latitudes. 51 Specifically, Doorack et al 51 examined SAD symptoms in patients with schizophrenia in Alaska and found that 36% had co-occurring SAD. Moreover, previous studies have suggested an association between onset of the first episode of schizophrenia and season (eg, Strous et al 52 ) . Additionally, studies conducted in the northern hemisphere found a summer peak of schizophrenia admissions in hospitals. [53] [54] [55] In England and Wales, for example, Hare and Walter 54 found a summer peak of schizophrenia admissions. Clarke et al 56 found a seasonal association in first-episode schizophrenia admissions in Ireland, although this association varied on an annual basis. In a subsequent study, Clarke et al 57 found that the seasonal association held only for first admissions and not for subsequent admissions. Shiloh et al 58 found a summer peak for schizophrenia admissions in Israel. In China, Tian et al 59 found a spring peak (March) in schizophrenia admissions, although they noted that they did not distinguish between first episodes and readmission, which, according to Clarke et al, 57 may be necessary to isolate seasonality effects. However, there are studies that found no seasonal variation in schizophrenia or that found patterns contrary to those previously reported. For example, Aviv et al 60 as well as Amr and Volpe 61 did not find any seasonal effect on admission rates. In the southern hemisphere, Davies et al 62 found a peak in first-episode schizophrenia admission in the winter (August), similar to Owens and McGorry. 63 In contrast, Daniels et al 64 did not find a seasonal association in admissions with diagnoses of schizophrenia and bipolar disorder in Tasmania.
There are certain clinical symptoms that overlap between SAD and schizophrenia, including cognitive deficits, social withdrawal, and changes in sleeping pattern. Furthermore, the incidence of schizophrenia has been found to be higher at higher latitudes, 65 a pattern that is shared with SAD, and it has been shown that there is a season of birth effect for schizophrenia, 66 and likewise for SAD, 67 which has led to the hypothesis that vitamin D plays a crucial role in the etiology of schizophrenia. 68 Vitamin D improves mood in healthy individuals 51 during winter and reduces depression scores in patients with SAD. 52 The results of this study suggest that, in addition to environmental modifiable risk factors such as ultraviolet B radiation, photoperiod, visible light intensity, vitamin D supplementation and levels, skin exposure (eg, sunscreen, reduced outdoor activities), and weight increase (resulting in lowering of vitamin D levels 69, 70 ), SAD and schizophrenia share previously unacknowledged genetic risk factors that deserve studies in their own right. However, our study provides evidence only for an overlap in genetic risk factors between schizophrenia and seasonality. Further evidence for an association between seasonality and schizophrenia is needed at the genetic, environmental, and clinical levels before seasonality can be considered as a component of schizophrenia.
In conclusion, we provide direct evidence for an expected genetic overlap in risk between bipolar disorder (but not major depressive disorder) and seasonality, and a somewhat less expected overlap between schizophrenia and seasonality. Further investigation of the links between bipolar disorder, schizophrenia, and SAD at both the clinical and molecular levels is warranted and may lead, in the long run, to studies that uncover novel therapeutic targets. 
